WMSA
KERX

Weiss Multi-Strategy Advisers’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-50,000
Closed -$499K – 533
2015
Q2 		$499K Buy
+50,000
New +$536K 0.02% 380
2015
Q1 		– Sell
-20,000
Closed -$283K – 567
2014
Q4 		$283K Buy
+20,000
New +$310K 0.01% 364

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Weiss Multi-Strategy Advisers's KERX Position: Q3 2018 in Review

Weiss Multi-Strategy Advisers sold out of Keryx Biopharmaceuticals Inc (KERX) in Q3 2018, closing a stake of 67,929 shares — an estimated $255K sold.

Weiss Multi-Strategy Advisers first reported a position in KERX in Q4 2013 and held it in 14 quarters. The position peaked at $561K in Q4 2015. 123 funds tracked by Wall St. Rank hold KERX as of Q3 2018.

  • Weiss Multi-Strategy Advisers reported no remaining Keryx Biopharmaceuticals Inc position as of Q3 2018 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 67,929 Keryx Biopharmaceuticals Inc shares in Q3 2018, an estimated $255K.
  • Weiss Multi-Strategy Advisers first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 14 quarters.
  • Weiss Multi-Strategy Advisers's Keryx Biopharmaceuticals Inc position peaked at $561K in Q4 2015.
  • 123 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q3 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.